We’ve placed a strategic focus on HER2 development to help address the ongoing unmet needs faced by patients and their families. Learn how the landscape of HER2-targeted agents in cancer care is evolving and how we’re continuing to build our HER2 platform to drive long-term impact for patients and their families

The pace of progress in oncology continues to accelerate, driven by a deeper understanding of tumor biology and increasingly precise therapeutic approaches. That momentum is particularly meaningful in rare cancers, where unmet need remains high and rigorous science has the potential to make a real difference for patients.

Corporate Sustainability and Social Impact, or CSSI, helps us embed the needs of patients, our people, communities, and the planet into how we operate and make decisions. It is a business discipline that supports trust, resilience, and long-term value.

We recognize that living with a complex sleep disorder extends far beyond the core symptoms and profoundly impacts every facet of a person’s life. For years, we have worked to better understand the complex, multifaceted realities faced by individuals living with these often-misunderstood conditions.

Each May, Brain Cancer Awareness Month highlights brain and other central nervous system cancers—some of the most complex and least understood. Despite recent advances, people with rare brain tumors still face delays in diagnosis, limited access to specialized care, and fewer treatment options when time matters most.

For families facing diffuse midline glioma, rapid progression and scarce options have long defined the journey. Hear how following the biology, learning from outliers, and uniting researchers, clinicians, advocates, and families led to meaningful progress and a new therapeutic option for patients with H3 K27M‑mutant disease.